POLYMERASE CHAIN REACTION MARKET ANALYSIS

Polymerase chain reaction (PCR) is used to amplify a specific segment of DNA through a thermal cycling protocol. Continuous technological advancement in the field of polymerase chain reaction are aimed to improve specificity, scalability and reliability in DNA amplification and thereby creating millions of amplicons of a target sequence in a short period of time. PCR is used for various applications, including the detection of pathogenic bacteria, disease diagnosis, molecular and genetic research, forensic DNA profiling, and parental testing. Rapid technological advancement in the polymerase chain reaction to deliver highly sensitive and optimized detection instrument, increasing prevalence of chronic and infectious disease, and growing research funding in gene therapy and molecular testing is expected to drive growth of the global polymerase chain reaction market over the forecast period.

The global polymerase chain reaction market is estimated to be valued at US$ 5,627.9 million in 2022 and is expected to exhibit a CAGR of 8.9% during the forecast period (2022-2030).

Figure 1. Global Polymerase Chain Reaction Market Share (%), by Product Type, 2022

To learn more about this report, request sample copy

Increasing numbers of product launches in polymerase chain reaction are expected to drive growth of the global polymerase chain reaction market

Key players in the polymerase chain reaction market are engaged in launching advanced and novel PCR instruments and consumables, which will allows rapid and easy nucleic acid amplification. For instance, in October 2017, Diatech Pharmacogenetics S.R.L., a provider of molecular diagnostic tools for precision medicine launched easyPGX: a ready-to-use in-vitro diagnostic real-time PCR product line and Helix: a polymerase chain reaction kit for the extraction of circulating free DNA from plasma.

Figure 2.Global Polymerase Chain Reaction Market Share (%), by Region, 2022

To learn more about this report, request sample copy

Increasing prevalence of chronic and infectious disease are driving growth of the global polymerase chain reaction market

Polymerase chain reaction is increasingly used in clinical diagnosis of infectious disease, nucleic acid amplification, paternity testing, DNA fingerprinting, detection and diagnosis of infectious disease, quality control, and personalized medicine. For instance, in March 2022, according to data published by Indian Council of Medical Research (ICMR), there will be a 12 percent rise in cancer cases in India by the 2027. The most common forms of cancer affecting the people of India are breast cancer, cervical cancer, and oral cancer. Furthermore, in May 2022, according to data published by National Center for Biotechnology Information, projected cancer burden in India for 2021 was 26.7 million and expected to increase to 29.8 million in 2025. In 2021 highest burden was in the north (2408 DALYsAMI per 100,000) and northeastern (2177 DALYsAMI per 100,000) regions of the India and higher among males. More than 40% of the total cancer burden was contributed by the seven leading cancer sites — lung (10.6%), breast (10.5%), oesophagus (5.8%), mouth (5.7%), stomach (5.2%), liver (4.6%), and cervix uteri (4.3%).

Global Polymerase Chain Reaction Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global polymerase chain reaction market, owing to application of polymerase chain reaction technique in detection of covid-19. For instance, in January 2020, according to data published by PubMed, zoonotic transmission of SARS coronavirus from animals to humans was detected using classical Reverse Transcription–Polymerase Chain Reaction (RT-PCR) assays that target a highly conserved sequence among coronaviruses. Reverse Transcription Polymerase Chain Reaction (RT-PCR) assays was firstly used to identify coronaviruses in bats.

Global Polymerase Chain Reaction Market: Key Developments

In March 2022, according to the U.S. Food and Drug Administration (FDA), a new highly sensitive, easy-to-use test for COVID-19 that requires a single swab and 15 minutes has received emergency use authorization (EUA) status from the U.S. Food and Drug Administration (FDA). Rapid Polymerase Chain Reaction (PCR) test was developed in March 2022 at Northwestern University’s Center for Innovation in Global Health Technologies (CIGHT), the point-of-care technology is being commercialized by Northwestern spinoff company, Minute Molecular Diagnostics.

Global Polymerase Chain Reaction Market: Restraint

The major factors that hinder growth of the global polymerase chain reaction market include advances in research are leading to generation of various alternative nucleic acid amplification methods. For instance, in September 2021, according to data published by ResearchGate, Nucleic Acid Amplification has been mentioned as alternative methods of Polymerase Chain Reaction (PCR). Isothermal amplification methods have been gaining attention, especially for point-of-care diagnosis and applications. These non-PCR based methods have been developed by mimicking the in vivo amplification mechanisms, while performing the amplification with high sensitivity, selectivity and allowing for high-throughput analysis.

Key Players

Major players operating in the global polymerase chain reaction market include F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., bioMérieux, S.A., Enzo Life Science, Inc., Abbott Laboratories, Takara Bio Inc., Becton, Dickinson and Company, and Danaher Corporation.